InvestorsHub Logo
icon url

sunspotter

07/23/22 4:06 PM

#391581 RE: Lemoncat #391578

Actually the fact there were twice as many SAEs and AEs in the brilacidin group compared to placebo suggests that there was in fact significant systemic absorption of brilacidin.

As OM by definition involves significant ulceration it’s entirely to be expected that some active would reach the blood stream.
icon url

williamssc

07/23/22 4:44 PM

#391582 RE: Lemoncat #391578

Being tested as a topical is best for now they could probably even add a numbing agent if needed.
And then there's this..

In the IPIX trial, treatment with Brilacidin in the modified Intent-to-Treat (mITT) population reduced the relative incidence of SOM by 65.0% compared to placebo. In the Per Protocol population, the relative incidence of SOM decreased by 80.3% compared to placebo.

https://www.baystreet.ca/stockstowatch/5021/A-Look-at-New-Oral-Mucositis-Drugs-Galera-Therapeutics-Capital-Raise-Points-to-Innovation-Pharmaceuticals-Being-Grossly-Undervalued